ArticleFrontiers in immunology2022

Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus.

Hao Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.